文献速递泌尿生殖与妇科肿瘤放疗

同步吉西他滨联合顺铂与图像引导调强放疗治疗局部晚期宫颈癌的I期试验

Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-04-22

这项开放标签、非随机、前瞻性I期剂量递增试验在局部晚期宫颈癌患者中评估图像引导调强放疗(IG-IMRT)能否提高同步顺铂联合吉西他滨的耐受性。35例患者中7例(20.0%)发生剂量限制性毒性(DLT);盆腔野队列采用GC序贯(吉西他滨先于顺铂)时估计最大耐受剂量(MTD)为100 mg/m2,而扩大野队列在首个剂量水平3例中2例发生DLT后关闭。结论认为IG-IMRT可使盆腔放疗联合顺铂时吉西他滨的同步剂量提高,但急性毒性仍受照射体积和化疗序贯影响。

要点

  • 盆腔野IG-IMRT联合顺铂时,吉西他滨GC序贯的估计MTD为100 mg/m2。
  • 扩大野队列在首个剂量水平3例中2例发生DLT后关闭。
  • 全体35例中7例(20.0%)发生DLT,急性毒性仍需关注。

核心结论

  • IG-IMRT可使局部晚期宫颈癌盆腔放疗联合顺铂时吉西他滨的同步剂量提高。
  • 该方案的急性毒性仍与照射体积和化疗序贯方式有关。

研究设计与样本

  • 开放标签、非随机、前瞻性I期剂量递增试验,在单个三级学术癌症中心开展(NCT01554410)。
  • 入组IB-IVA期宫颈癌患者,宫颈完整或子宫切除后盆腔/腹主动脉旁淋巴结残留/复发,接受根治性盆腔或扩大野放化疗。
  • 放疗为IG-IMRT:盆腔±腹主动脉旁淋巴结45-47.6 Gy/25-28次,同步淋巴结推量至53.2-59.4 Gy/28次。
  • 化疗为5周期同步每周顺铂40 mg/m2联合吉西他滨剂量递增(50、75、100或125 mg/m2)。
  • 按盆腔野或扩大野及吉西他滨在顺铂后(CG)或前(GC)分层,DLT监测至放化疗后30天,主要终点为DLT概率≤20%的MTD。

主要发现

  • 2011年2月至2019年6月共注册35例患者,7例(20.0%)发生DLT。
  • 盆腔野队列采用GC序贯时估计MTD为100 mg/m2,高于该方案既往报道的MTD。
  • 扩大野队列在首个剂量水平3例中2例发生DLT后关闭。

关键数值与推荐

  • 主要终点为DLT概率≤20%对应的MTD。
  • 盆腔野队列GC序贯的估计MTD为100 mg/m2。
  • 扩大野队列首个剂量水平3例中2例发生DLT后关闭。

临床怎么用

  • 对局部晚期宫颈癌行盆腔IG-IMRT时,可考虑同步顺铂联合吉西他滨GC序贯,吉西他滨剂量可探索至100 mg/m2。
  • 扩大野放疗时该联合方案急性毒性较高,需谨慎选择并密切监测。

局限性

  • 为单中心、开放标签、非随机I期试验,样本量35例。
  • 扩大野队列因DLT提前关闭,相关数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The use of concurrent doublet chemotherapy with radiation for locoregionally advanced cervical cancer (LACC) is limited by gastrointestinal and hematologic toxicity. By reducing radiation dose to bowel and bone marrow, image guided intensity modulated radiation therapy (IG-IMRT) may improve chemotherapy tolerance. The goal of this study was to determine whether IG-IMRT could lead to improved tolerance to concurrent cisplatin and gemcitabine for LACC. METHODS AND MATERIALS: We conducted an open-label, nonrandomized, prospective phase 1 dose escalation trial at a tertiary academic cancer center (ClinicalTrials.gov identifier: NCT01554410). We enrolled patients with stage IB-IVA cervical cancer, with either an intact cervix or posthysterectomy with residual/recurrent pelvic or paraortic nodal involvement, undergoing radical pelvic or extended field chemoradiation therapy. Treatment consisted of chemoradiation with IG-IMRT (45-47.6 Gy, 25-28 fractions to the pelvis ± paraortic nodes with simultaneous nodal boost to 53.2-59.4 Gy, 28 fractions) plus 5 cycles of concurrent weekly cisplatin 40 mg/m2 with escalating doses of gemcitabine (50, 75, 100, or 125 mg/m2). Cohorts were separated preregistration according to whether the patient received pelvic or extended field IG-IMRT and whether gemcitabine followed (CG) or preceded (GC) cisplatin delivery. Dose-limiting toxicity (DLT) events were monitored up to 30 days after chemoradiation therapy. The primary endpoint was maximum tolerated dose (MTD) resulting in DLT probability ≤20%. RESULTS: Between February 2011 and June 2019, 35 patients were registered. Overall, 7 patients (20.0%) experienced DLTs. For the pelvic field cohort, the estimated MTD was 100 mg/m2 with GC sequencing, which is higher than the previously reported MTD for this regimen. The extended field cohort was closed after 2 of 3 patients experienced a DLT at the first dose level. CONCLUSIONS: IG-IMRT can permit higher doses of concurrent gemcitabine with cisplatin and pelvic radiation for LACC. However, acute toxicity remains a factor with this regimen, depending on radiation volume and chemotherapy sequencing.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Mell LK, Xu R, Yashar CM, et al. Phase 1 Trial of Concurrent Gemcitabine and Cisplatin with Image Guided Intensity Modulated Radiation Therapy for Locoregionally Advanced Cervical Carcinoma. Int J Radiat Oncol Biol Phys. 2020. PMID: 32334034. doi:10.1016/j.ijrobp.2020.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。